J Intern Med:每月高剂量维生素D能否改善社区居住老年人的骨密度?

2017-12-05 吴星 环球医学

2017年11月,发表在《J Intern Med》的一项由新西兰和美国科学家进行的随机对照试验,考察了社区居住的老年人中,每月高剂量维生素D对骨密度的影响。

2017年11月,发表在《J Intern Med》的一项由新西兰和美国科学家进行的随机对照试验,考察了社区居住的老年人中,每月高剂量维生素D对骨密度的影响。

背景:严重缺乏维生素D导致骨软化,但社区中维生素D补充的试验尚未平均证实其对成人骨矿物质密度(BMD)或骨折风险的受益。

目的:确定每月补充高剂量维生素D是否影响普通人群和25-羟基维生素D水平较低的人群的BMD。

方法:社区居住的老年人试验的2年亚研究。共有452例参与者被随机化至接受每月维生素D3 100000 IU或安慰剂。主要终点为腰椎BMD的变化。预定义探索性分析以确定维生素D对BMD影响的基线25-羟基维生素D阀值。

结果:意向治疗分析显示,腰椎(组间差异0.0071 g cm-2,95% CI:-0.0012,0.0154)或全身没有显着治疗效果,但在2年时间内,两个髋部部位BMD均显着减少~1/2%。基线25-羟基维生素D与治疗效果之间有显着的相互作用(P=0.04)。基线25-羟基维生素D≤30 nmol L-1(n=46)时,脊柱和股骨部位的组间BMD变化~2%,脊柱和股骨颈的BMD变化显着,但对全身BMD无影响。当基线25-羟基维生素D>30 nmol L?1时,差异达~1/2%且仅在全髋显着。

结论:本亚研究显示,社区居住的老年人的非靶向维生素D补充对BMD没有显着临床获益。探索性分析显示,基线25-羟基维生素D≤30 nmol L-1时,可产生有意义获益。这代表,老年成人骨健康基于试验的维生素D缺乏的定义迈出了显着一步。

原始出处

Reid IR, Horne AM, Mihov B,et al. Effect of monthly high-dose vitamin D on bone density in community-dwelling older adults substudy of a randomized controlled trial. J Intern Med. 2017 Nov;282(5):452-460. doi: 10.1111/joim.12651.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1942082, encodeId=866519420828a, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Apr 25 01:26:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275731, encodeId=a3792e5731e3, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 13:00:15 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395730, encodeId=dcc31395e3007, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Dec 07 06:26:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608323, encodeId=35531608323f9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Dec 07 06:26:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267045, encodeId=020f26e045b5, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Dec 05 18:51:10 CST 2017, time=2017-12-05, status=1, ipAttribution=)]
    2018-04-25 amy0550
  2. [GetPortalCommentsPageByObjectIdResponse(id=1942082, encodeId=866519420828a, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Apr 25 01:26:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275731, encodeId=a3792e5731e3, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 13:00:15 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395730, encodeId=dcc31395e3007, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Dec 07 06:26:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608323, encodeId=35531608323f9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Dec 07 06:26:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267045, encodeId=020f26e045b5, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Dec 05 18:51:10 CST 2017, time=2017-12-05, status=1, ipAttribution=)]
    2018-01-05 1dd8c52fm63(暂无匿称)

    了解了解.学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1942082, encodeId=866519420828a, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Apr 25 01:26:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275731, encodeId=a3792e5731e3, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 13:00:15 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395730, encodeId=dcc31395e3007, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Dec 07 06:26:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608323, encodeId=35531608323f9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Dec 07 06:26:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267045, encodeId=020f26e045b5, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Dec 05 18:51:10 CST 2017, time=2017-12-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1942082, encodeId=866519420828a, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Apr 25 01:26:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275731, encodeId=a3792e5731e3, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 13:00:15 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395730, encodeId=dcc31395e3007, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Dec 07 06:26:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608323, encodeId=35531608323f9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Dec 07 06:26:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267045, encodeId=020f26e045b5, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Dec 05 18:51:10 CST 2017, time=2017-12-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1942082, encodeId=866519420828a, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Apr 25 01:26:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275731, encodeId=a3792e5731e3, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 13:00:15 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395730, encodeId=dcc31395e3007, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Dec 07 06:26:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608323, encodeId=35531608323f9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Dec 07 06:26:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267045, encodeId=020f26e045b5, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Dec 05 18:51:10 CST 2017, time=2017-12-05, status=1, ipAttribution=)]
    2017-12-05 131****1460

    学习了受益匪浅

    0

相关资讯

J Autoimmun:维持充足的维生素D水平可以帮助预防类风湿性关节炎

伯明翰大学(University of Birmingham)领导的研究发现,维持充足的维生素D水平可能有助于预防风湿性关节炎等炎症疾病的发生。

Lancet Respir Med:维生素D能否降低低基线维生素D水平哮喘患者加重的发生率?

2017年10月,发表在《Lancet Respir Med》上的一项系统评价和Meta分析,研究了补充维生素D 能否降低低基线维生素D水平患者哮喘加重的发生率。研究结果表明:维生素D补充可降低需要全身糖皮质激素治疗的哮喘加重的总体发生率。但未找到明确证据表明,该干预效果在各患者亚组中具有差异。

BMJ:孕期维生素D补充对产妇及新生儿结局的影响

研究认为,大多数孕期维生素D补充对孕妇及新生儿影响的研究规模较小,证据质量偏弱,不足以作为临床指导或政策建议

J Am Heart Assoc:补充维生素D对中心血压参数有何影响?

有报道称,缺乏维生素D的人更有可能患高血压、II型糖尿病以及高血脂。2017年10月,发表在《J Am Heart Assoc》的一项双盲、安慰剂对照亚研究调查了每月、高剂量、长期补充维生素D对中心血压(BP)参数的影响。结果表明,每月高剂量补充维生素D持续1年可降低缺乏维生素D成人的中心BP参数,但不能降低总样本的参数。

JCEM:维生素D对于成人囊性纤维化患者肠道菌群的影响

众多周知肠道菌群紊乱可能会加重囊性纤维化(CF)的严重程度,而维生素D缺乏又是CF患者常见的共发病,可能会影响肠道菌群的组成。近日在JCEM上发表的一篇文章则比较了维生素D充足和不足的CF患者的菌群,并评估了每周高剂量维生素D3的补充方案对于维生素D缺乏(25(OH)D<30ng/ml)的CF患者的肠道和呼吸道微生物的影响。

J Am Heart Assoc:维生素D能改善老年人血压、动脉硬化和心脏功能吗

2017年10月,发表在《J Am Heart Assoc》的BEST-D(Biochemical Efficacy and Safety Trial of Vitamin D,维生素D的生化功效和安全性试验)试验,考察了补充维生素D 1年对老年血压、动脉硬化和心脏功能的影响。